Skip to main content
SpringerLink
Log in

Konjugat- und/oder Polysaccharidvakzine?

Aktuelle Empfehlungen zur Pneumokokken-Impfung

Pneumococcal vaccination — Update 2015

  • FORTBILDUNG_ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Pneumokokken-Infektionen sind weltweit ein ernst zu nehmendes Gesundheitsproblem. Um gefährdete Personen zu schützen, wurden verschiedene Pneumokokken-Impfstoffe entwickelt. Der nachfolgende Beitrag imformiert Sie über die aktuellen Impfempfehlungen und -schemata.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9.

    Article  CAS  PubMed  Google Scholar 

  2. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.

    Article  PubMed  Google Scholar 

  3. Robert-Koch-Institut (RKI). Mitteilung der ständigen Impfkommission (STIKO) am Robert-Koch-Institut, Stellungnahme zur Impfung Erwachsener gegen Pneumokokken. Epidemiologisches Bulletin. 2012 2012;17:55–6.

    Google Scholar 

  4. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114–25.

    Article  CAS  PubMed  Google Scholar 

  5. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS ONE. 2015;10(7):e0131494.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–8.

    Article  PubMed  Google Scholar 

  7. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61(3):189–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008;26(33):4284–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28(43):7063–9.

    Article  PubMed  Google Scholar 

  10. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. Bmj. 2010;340:c1004.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493–500.

    Article  CAS  PubMed  Google Scholar 

  12. Ærtqvist Å, Hedlund J, Burman L-Å, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. The Lancet. 1998;351(9100):399–403.

    Article  Google Scholar 

  13. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48–58.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Törling J, Hedlung J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine. 2003;22(1):96–103.

    Article  PubMed  Google Scholar 

  15. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma, B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal-vaccine-naíve adults. Vaccine. 2013;31(35):3577–84.

    Article  CAS  PubMed  Google Scholar 

  16. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenburg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma, B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31(35):3585–93.

    Article  CAS  PubMed  Google Scholar 

  17. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naíve adults 60-64 years of age. Vaccine 2014;32:2364–74.

    Article  CAS  PubMed  Google Scholar 

  18. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594–602.

    Article  CAS  PubMed  Google Scholar 

  19. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009;49:1318–25.

    Article  CAS  PubMed  Google Scholar 

  20. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska Native adults 55-70 years of age. Clin Infect Dis 2009;49:241–8.

    Article  CAS  PubMed  Google Scholar 

  21. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2011. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee

Download references

Author information

Authors and Affiliations

  1. Klinik für Lungen- und Bronchialmedizin, Klinikum Kassel, Universitätsklinik der Universität Southampton, Möncheberg-Str. 41–43, D-34125, Kassel, Deutschland

    Adrian Gillissen M.Sc.

Authors
  1. Adrian Gillissen M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian Gillissen M.Sc..

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillissen, A. Aktuelle Empfehlungen zur Pneumokokken-Impfung. MMW - Fortschritte der Medizin 157, 51–54 (2015). https://doi.org/10.1007/s15006-015-3732-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-3732-8

Keywords

Search

Navigation